06.07.2012 - The French pharma giant is preparing for a major overhaul of activities in its home market.
Exact numbers are not yet final, but French unions already fear the worst. An estimate of 2,000 jobs lost is “probably close to reality,” said Thierry Bodin, a representative of the CGT union after a meeting with managers today. Europe’s third-biggest drugmaker wants to regroup its research in the Paris region and around Lyon, he said. This might be the end for research in Toulouse, where the blockbuster Plavix blood thinner was developed, and Montpellier. The company also plans to eliminate support functions and cut jobs at its Pasteur vaccine division, Bodin said.
Reuters reports, that Chief Executive Chris Viehbacher told employees that the unspecified number of job cuts, at its Toulouse and Montpellier sites, would be achieved through voluntary redundancies, early retirement and internal mobility. Manufacturing sites in France would not be affected by the project. Jean-Marc Podvin, a spokesman for Sanofi, said in a telephone interview with Bloomberg Businessweek, that no job cut figures were given and all options remain open for Toulouse. Montpellier could become a centre focused on clinical development, he added.
The company’s CEO Viehbacher began to restructure Sanofi in 2009 reducing headcount, closing plants and dropping the least promising projects. As part of a strategic shift, the French drugmaker is aiming at reducing internal research and having other actors, such as small biotechs, academic research to find new molecules and vaccines.
In its course to concentrate on its core competencies, Sanofi has decided to divest its 19.3% stake in the Yves Rocher Group, which operates in a variety of sectors, including cosmetics, home care products and clothing. The Rocher family which already controls most of the company will buy the shares and raise its stake to more than 95%.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more